<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow specimens obtained from 54 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 7 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> evolving from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were retrospectively examined for the presence of micromegakaryocytes defined as cells of less than 30 microns in diameter with one or two nuclei </plain></SENT>
<SENT sid="1" pm="."><plain>At least 25 megakaryocytes were counted in each patient </plain></SENT>
<SENT sid="2" pm="."><plain>Micromegakaryocytes were found in 17 cases (31%), M1:1/11, M2:5/18, M3:0/4, M4:5/12, M5:1/4, M6:4/4, M7:1/1 </plain></SENT>
<SENT sid="3" pm="."><plain>The median age of the patients was higher in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with micromegakaryocytes (57 years) than in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without micromegakaryocytes (41 years) (p = 0.014) </plain></SENT>
<SENT sid="4" pm="."><plain>Chromosomal analysis revealed that deletion of 5 or 5q-, 7 or 7q- was recognized only in the group of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with micromegakaryocytes and that t(15;17), t(8:21) and inv (16) were not recognized in this group </plain></SENT>
<SENT sid="5" pm="."><plain>Micromegakaryocytes were identified in each bone marrow specimen obtained from 9 of 10 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with trilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The complete remission rate was significantly lower in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with micromegakaryocytes (33%) than in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without micromegakaryocytes (86%) (p = 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>The duration of survival of the patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with micromegakaryocytes was shown to be shorter than that of the patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without micromegakaryocytes (p = 0.017) </plain></SENT>
<SENT sid="8" pm="."><plain>Micromegakaryocytes were recognized in <z:hpo ids='HP_0000001'>all</z:hpo> of 7 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> evolving from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The presence of micromegakaryocytes in bone marrow of the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> indicates a subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with poor prognosis that may be closely associated with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
</text></document>